论文部分内容阅读
本文报告ＣＡ（Ｅ）Ｐ方案，即环磷酰胺、阿霉素或表阿霉素、顺铂治疗非小细胞肺癌的近期疗效。本组共１２５例，男性１１１例，女性１４例。年龄从１７岁至７２岁，平均年龄５３．５岁。鳞癌８９例，腺癌３６例。采用ＣＡ（Ｅ）Ｐ方案联合化疗，总有效率为５２．０％（６５／１２５）。此方案对鳞、腺癌疗效无差异。本组病例疗效与分期、病人年龄、机体功能状态有关。阿霉素对心肌毒性反应，做了心肌酶谱检查，全组病例化疗前、后心肌酶谱改变不大，无统计学意义。对１８例化疗前心电有变化者，化疗三个周期后，心肌改变明显，统计学处理有意义，Ｐ＜０．０１。提示我们在化疗过程中有心电图改变的病人，应慎用阿霉素或表阿霉素。
This article reports the short-term efficacy of the CA(E)P regimen, cyclophosphamide, doxorubicin or epirubicin, and cisplatin in the treatment of non-small cell lung cancer. There were 125 cases in this group, 111 males and 14 females. Age from 17 to 72 years old, with an average age of 53.5 years old. 89 cases of squamous cell carcinoma and 36 cases of adenocarcinoma. Using CA(E)P regimen combined with chemotherapy, the total effective rate was 52.0% (65/125). This program has no effect on squamous cell carcinoma and adenocarcinoma. The efficacy of this group of patients was related to stage, patient’s age, and body function status. The cardiotoxicity of doxorubicin was examined by myocardial enzyme examination. There was no significant change in the myocardial enzyme spectrum of the whole group of patients before and after chemotherapy. For 18 patients with changes in electrocardiogram before chemotherapy, after three cycles of chemotherapy, myocardial changes were significant and statistically significant, P<0.01. It is suggested that we should use doxorubicin or epirubicin with caution in patients with electrocardiographic changes during chemotherapy.